Quick Takeaways
- VANGUARD GROUP INC filed SCHEDULE 13G for Corvus Pharmaceuticals Inc Common Stock (CRVS).
- Disclosed ownership: 5.2%.
- Date of event: 31 Dec 2025.
VANGUARD GROUP INC - 31 Dec 2025 SCHEDULE 13G Report for Corvus Pharmaceuticals Inc Common Stock (CRVS)
- Filing Manager
- VANGUARD GROUP INC
- Reporting Manager
- The Vanguard Group
- Symbol
- CRVS
- Shares outstanding
- 74,777,645 shares
- Disclosed Ownership
- 3,873,482 shares
- Ownership
- 5.2%
- Form type
- SCHEDULE 13G
- Filing time
- 30 Jan 2026, 13:26:05 UTC
- Date of event
- 31 Dec 2025
- Next filing
- 26 Mar 2026
- SEC
- View on sec.gov
Quoteable Key Fact
"VANGUARD GROUP INC disclosed 5.2% ownership in Corvus Pharmaceuticals Inc Common Stock (CRVS) on 31 Dec 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 30 Jan 2026, 13:26.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| The Vanguard Group | 5.2% | 3,873,482 | 0 | 472,993 | Ashley Grim | Head of Global Fund Administration |